Skip to main content

Table 3 Multivariate analysis of factors affecting intracranial PFS and OS in the patients

From: Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

FactorsIntracranial PFSOS
HR95%CIpHR95%CIp
All patients
 Gender1.100.50–2.410.820.670.33–1.360.27
 Smoking1.120.53–2.380.770.840.44–1.630.61
 Age0.990.65–1.520.971.400.33–1.360.11
 Histology0.820.54–1.230.331.400.93–2.130.11
 KPS0.900.58–1.400.630.970.65–1.460.88
 Number of BM0.890.56–1.410.610.880.57–1.350.55
 Extracranial metastases0.960.53–1.740.891.150.66–2.010.63
 Primary disease control0.100.93–2.160.100.920.61–1.380.68
Patients with Lung-molGPA 0–2
 Gender1.040.52–2.090.911.000.44–2.271.00
 Smoking0.820.40–1.680.590.980.43–2.200.95
 Age0.850.52–2.090.571.320.75–2.300.33
 Histology0.910.52–1.560.720.650.37–1.140.13
 KPS0.610.32–1.150.131.380.76–2.500.30
 Number of BM0.790.47–1.330.381.260.74–2.150.40
 Extracranial metastases0.640.37–1.110.111.060.58–1.930.86
 Primary disease control1.390.83–2.320.210.880.49–1.590.67
Patients with Lung-molGPA 2.5–4
 Gender1.110.66–1.850.700.810.50–1.310.39
 Smoking1.070.65–1.750.800.890.56–1.420.63
 Age1.070.77–1.480.701.491.09–2.050.01
 Histology0.790.58–1.090.151.120.81–1.540.51
 KPS1.020.74–1.390.931.060.78–1.430.73
 Number of BM0.970.71–1.340.860.980.72–1.340.91
 Extracranial metastases1.190.87–1.640.281.401.01–1.930.04
 Primary disease control1.370.10–1.890.051.040.76–1.420.81
  1. Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, KPS Karnofsky Performance Status, BM brain metastasis, Lung-molGPA, Lung Cancer Molecular Markers Graded Prognostic Assessment